University of Pittsburgh School of Medicine

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, November 8, 2023
MSD, Society for Immunotherapy of Cancer, Plasma, AIM, NYSE, Ovarian cancer, Biomarker, Therapy, Tumor necrosis factor, Viral, TNF, Pembrolizumab, DSM-IV codes, Cisplatin, PBMC, CXCL9, Research, CXCR3, University of Pittsburgh School of Medicine, Function (mathematics), SITC, Immunotherapy, CXCL11, Perforin-1, Cancer, Annual general meeting, University, Tumor microenvironment, CXCL10, Wilfrid Sellars, TME, IP, Patient, UPMC, Pharmaceutical industry, Merck

OCALA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced encouraging translational data from an ongoing Phase 2 clinical trial utilizing AIM’s drug Ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer.

Key Points: 
  • The data was also made available at the conference in a poster presentation .
  • Sequential sampling of the IP cavity showed an increase in cellularity immediately after treatment consistent with an “acute” pro-inflammatory reaction.
  • These data show a similar profile to previously published data from Roswell Park in Stage 4 triple negative breast cancer.
  • Additionally, we hope to announce topline interim survival results from UPMC in the near future.”
    For more information about the Phase 2 clinical trial of platinum-sensitive advanced recurrent ovarian cancer utilizing Ampligen®, visit clinicaltrials.gov and reference identifier: NCT03734692.

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Monday, October 30, 2023
AIM, NYSE, UPMC Hillman Cancer Center, IV, Therapy, Viral, Society for Immunotherapy of Cancer, DSM-IV codes, Cisplatin, MD, Research, University of Pittsburgh School of Medicine, SITC, Immunotherapy, Disease, COVID-19, Cancer, Annual general meeting, University, Society, Wilfrid Sellars, Patient, UPMC, Pharmaceutical industry

OCALA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine (“UPMC") has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1 – 5, 2023 in San Diego, CA and virtually.

Key Points: 
  • OCALA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine (“UPMC") has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1 – 5, 2023 in San Diego, CA and virtually.
  • The abstract concerns a Phase 2 single arm efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with AIM’s drug Ampligen and IV infusion of the checkpoint inhibitor pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer.
  • The abstract authors include Robert Edwards, MD, Chief Medical Officer of the UPMC Community and Ambulatory Services Division and Co-Director of the Women’s Cancer Research Center at the UPMC Hillman Cancer Center.
  • Details for the presentation are as follows:

October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology

Retrieved on: 
Friday, October 20, 2023
Science, Survival, FDA, University of Pittsburgh School of Medicine, Associate, Clinical professor, Life, Internet, Lung cancer, Literature, Physician, Mortality, News, Doctor of Philosophy, Breast Cancer Awareness Month, Breast cancer, CPI, TNBC, ClinicalTrials.gov, Trust, Letter, Life expectancy, Disease, Risk, Partnership, University of Pittsburgh, Personalized medicine, Immunotherapy, University, Sandra, Figure, Woman, Wilfrid Sellars, Fast track (FDA), FACP, Cancer, Therapy, BCT, Weill Cornell Medicine, Diagnosis, Patient, TSX, Mayo Clinic, Liquor, Pharmaceutical industry, Birth control, Medical imaging, MD

The overall risk of a woman in the United States developing breast cancer sometime in her life is about 13%.

Key Points: 
  • The overall risk of a woman in the United States developing breast cancer sometime in her life is about 13%.
  • This means there is an approximately 1 in 8 chance she will develop breast cancer;
    Approximately 43,170 women and 530 men are expected to die of breast cancer in the U.S. in 2023, making breast cancer the 2nd leading cause of cancer death in women (after lung cancer) in the U.S.
  • I am writing this letter during Breast Cancer Awareness month to alert all to the devastation of advanced breast cancer.
  • While the focus of the month is on early detection, as it should be, I highlight our recent accomplishments in the fight against advanced breast cancer, an incurable disease.

Global Platform Study Presents Results to Guide Care of Severely Ill Patients With COVID-19 Using Routinely Available Drugs – Simvastatin and Vitamin C

Retrieved on: 
Wednesday, October 25, 2023
Science, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Hospitals, Clinical Trials, WHO, Urinary tract infection, Survival, FRCP, Patient, Vitamin C, Simvastatin, Royal Victoria Hospital, Montreal, Bronchopneumonia, MPH, Global Coalition Against Pneumonia, Oregon Health & Science University, University, Respiratory tract infection, JAMA, Professor, Vitamin, Multimedia, Queen's University Belfast, University of Pittsburgh School of Medicine, Learning, Critical Care Medicine (journal), COVID, Clinical trial, Intensive care unit, Hospital, NEJM, Probability, Pittsburgh, European Society of Clinical Microbiology and Infectious Diseases, Wilfrid Sellars, SUNY Downstate Health Sciences University, Hospice and palliative medicine, Intensive care medicine, Royal Victoria Hospital, UPMC, Consultant, Ohio State University Wexner Medical Center, Pharmaceutical industry, Dietary supplement, MD

Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.

Key Points: 
  • Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.
  • Through harmonizing two clinical trials – REMAP-CAP and LOVIT-COVID – over 2500 patients in 20 countries took part, including both critically ill and non-critically ill patients with COVID-19 in hospital.
  • It was shown that high dose vitamin C did not improve outcomes for patients.
  • Intravenous Vitamin C for Patients Hospitalized with COVID-19: Two Harmonized Randomized Clinical Trials.

Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Plasma, AD, Simoa, Food, Biomarker, CSF, Neurology, Pathology, Psychiatry, Threonine, Deficit spending, Lucent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doctor of Philosophy, PET, Cerebrospinal fluid, CLIA, University of Pittsburgh School of Medicine, Diagnosis, Antibody, Alzheimer's disease, Blood, DSM-IV codes, University, Wilfrid Sellars, Patient, Associate, Medical imaging, Medical device

Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217.

Key Points: 
  • Lucent Diagnostics, a diagnostics brand of Quanterix Corporation (NASDAQ: QTRX), today announced expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217.
  • p-Tau 217 has emerged as a top performing biomarker for Alzheimer’s pathology, enabling clinical sensitivity and specificity in blood.
  • Highly sensitive and specific blood-based biomarker tests have the potential to speed diagnosis and expand access to treatments for millions of individuals with early Alzheimer’s disease.
  • LucentAD p-Tau 217 leverages the combination of Quanterix’s ultra-sensitive Simoa® technology and J&J Innovative Medicine’s extensively studied p-Tau 217 antibodies to provide high accuracy with a simplified workflow.

Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2

Retrieved on: 
Monday, October 16, 2023
Skin temperature, Pfizer–BioNTech COVID-19 vaccine, Vaccine, RNA, RBD, Immunity, Safety, University, Italian LNP Cup, University of Pittsburgh School of Medicine, MedRxiv, Principal, Temperature, Therapy, Wilfrid Sellars, Clinical trial, SARS-CoV-2, Messenger, Skin

BALTIMORE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its mRNA platforms, today announced promising data from a Phase 1/2 trial (NCT04863131) evaluating EXG-5003, a SARS-CoV-2 vaccine developed with the Company’s temperature controllable self-replicating RNA (c-srRNA) technology. The data, published on medRxiv, demonstrate no safety concerns with EXG-5003 and induction of cellular (T cell-mediated) immunity. With clinical evidence that the c-srRNA platform is safe and can produce a T cell-mediated response, the Company is exploring its potential for the development of vaccines, cell therapies and immunotherapies for several indications.

Key Points: 
  • The data, published on medRxiv , demonstrate no safety concerns with EXG-5003 and induction of cellular (T cell-mediated) immunity.
  • The results from this trial suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.
  • This allows for the vaccine to be delivered intradermally, which is a method that’s been shown to induce strong T cell-mediated immunity.
  • Data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.

BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic

Retrieved on: 
Wednesday, October 11, 2023
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mayo Clinic, TSX, Doctor of Philosophy, Bria, KOL, University, Survival, University of Pittsburgh School of Medicine, Therapy, BCT, FACP, Wilfrid Sellars, Fast Track, Literature, Patient, Pharmaceutical industry, MD

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that it will host a virtual KOL event on Bria-IMT™ potential in advanced metastatic breast cancer on Thursday, October 26, 2023 at 10:00am ET.

Key Points: 
  • PHILADELPHIA and VANCOUVER, British Columbia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that it will host a virtual KOL event on Bria-IMT™ potential in advanced metastatic breast cancer on Thursday, October 26, 2023 at 10:00am ET.
  • To register for the event, please click here .
  • The event will feature KOLs Adam M. Brufsky, MD, PhD, FACP (University of Pittsburgh School of Medicine) and Saranya Chumsri, MD (Mayo Clinic) who will discuss the unmet medical need and current treatment landscape for patients suffering from advanced metastatic breast cancer, along with the combination study of Bria-IMT™ with immune check point inhibitor.
  • The event’s agenda is summarized below:
    BriaCell Virtual KOL Event Agenda – October 26, 2023

Tilak Healthcare Raises €10 Million to Continue Growing Its Leading Ophthalmological Telemedicine Offering

Retrieved on: 
Thursday, October 12, 2023
Health Technology, Telemedicine, Virtual Medicine, Other Health, Technology, Finance, Audio, Video, Optical, Professional Services, Biometrics, Medical Devices, Electronic Games, Other Technology, Biotechnology, Software, Entertainment, Health, Telehealth, Multimedia, Health care, Investment, Diabetic retinopathy, University of Pittsburgh School of Medicine, University, Gameloft, Elaia, Visual impairment, Clipperton, World Health Organization, AMD, Paratriathlon, CE, Wilfrid Sellars, Tilaka, Retina, Patient, Quality of life, Medical device, Pharmaceutical industry, Financial adviser, Ophthalmology

Tilak Healthcare , a pioneer and leading player in the field of ophthalmological digital health, has raised €10 million in a funding round led by Elaia and Cap Horn.

Key Points: 
  • Tilak Healthcare , a pioneer and leading player in the field of ophthalmological digital health, has raised €10 million in a funding round led by Elaia and Cap Horn.
  • This new funding round brings Tilak Healthcare’s total funding to €22 million since it was founded within the iBionext ecosystem in 2016.
  • Tilak Healthcare and Théa’s extended collaboration will deploy OdySight with the goal to develop new opportunities for healthcare, for both patients and healthcare professionals.
  • As part of this funding round, Clipperton acted as sole financial advisor to Tilak Healthcare.

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

Retrieved on: 
Tuesday, October 3, 2023
COPD, PDE4, Maintenance, University, Quality of life, PDE3, University of Pittsburgh School of Medicine, Associate, Chronic obstructive pulmonary disease, VRNA, US, MD, Patient, Risk, PDUFA, Wilfrid Sellars, Pharmaceutical industry, Medicine

LONDON and RALEIGH, N.C., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces four presentations on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at CHEST Annual Meeting (“CHEST”) 2023. The data are published in the CHEST Annual Meeting on-line supplement. Ensifentrine is Verona Pharma’s investigational dual PDE3 and PDE4 inhibitor, a potential first-in-class product currently under review by the US FDA for the maintenance treatment of COPD.

Key Points: 
  • The data are published in the CHEST Annual Meeting on-line supplement.
  • Ensifentrine is Verona Pharma’s investigational dual PDE3 and PDE4 inhibitor, a potential first-in-class product currently under review by the US FDA for the maintenance treatment of COPD.
  • Ensifentrine’s combined bronchodilator and non-steroidal anti-inflammatory activity could lead to meaningful benefits in a broad population of COPD patients.
  • Details of Verona Pharma’s presentations are listed below and linked to the CHEST website:
    For further information please contact:

Icahn School of Medicine at Mount Sinai Licenses Next-Generation Diagnostic Test Epigenetic /AI Platform to GNOMX Corp.

Retrieved on: 
Monday, September 18, 2023
Infection, Yale School of Medicine, Business development, DARPA, University, Lyme disease, Planetary Observer program, ECHO, Prognosis, Research, COVID, University of Pittsburgh School of Medicine, Department of Neurology, Xuanwu hospital, Doctor of Philosophy, Princeton University, Icahn School of Medicine at Mount Sinai, Sepsis, MSIP, Patient, Artificial intelligence, Diagnosis, Policy, Health, Mount Sinai Health System, Wilfrid Sellars, Epigenetics, Gene, Vaccine, Pharmaceutical industry, Management, MD, Neurology, Medicine

NEW YORK, Sept. 18, 2023 /PRNewswire-PRWeb/ -- The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases.

Key Points: 
  • The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases.
  • NEW YORK, Sept. 18, 2023 /PRNewswire-PRWeb/ -- The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases.
  • The GNOMX epigenetic diagnostic platform includes technology developed by Mount Sinai faculty and was optioned by Mount Sinai to GNOMX.
  • Mount Sinai and Mount Sinai faculty, including Dr. Sealfon, have a financial interest in this technology and in GNOMX pursuant to the Mount Sinai Intellectual Property Policy.